Phillips & Cohen partner Colette Matzzie contributes insights to a Bloomberg Law article about how pharmaceutical companies seeking patent extensions on brand-name drugs may encounter new legal challenges stemming from the False Claims Act.
Drug companies that allegedly defrauded the government to extend monopolies on brand name drugs face novel legal challenges under the False Claims Act from a patent lawyer who says the cases are a new front in the battle over pricey medications.
“I find this to be a very both novel but also compelling and creative potential use of the False Claims Act,” said Colette Matzzie, a whistleblower attorney and partner at Phillips & Cohen LLP, who is not involved in the case. “It’s absolutely correct, if the allegations are true, that there is an upstream fraud in a sense.”
Read the full article, “Drug Patents Face New Scrutiny in Novel False Claims Lawsuits,” on Bloomberg Law’s website.